EP4232161A1 — Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
Assigned to Dana Farber Cancer Institute Inc · Expires 2023-08-30 · 3y expired
What this patent protects
The present disclosure relates to compounds of formula I that are capable of inhibiting creatine kinase. The present disclosure also relates to methods of treating cancer, such as hematological malignancies.
USPTO Abstract
The present disclosure relates to compounds of formula I that are capable of inhibiting creatine kinase. The present disclosure also relates to methods of treating cancer, such as hematological malignancies.
Drugs covered by this patent
- Briviact (BRIVARACETAM) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.